CALGB 60301: SORAFENIB FOR SOLID TUMORS AND HAM MALIGNANCIES

CALGB 60301：索拉非尼治疗实体瘤和火腿恶性肿瘤

• 批准号: 7377558
• 负责人: ELIZABETH CLAIRE DEES
• 金额: $ 1.76万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377558
• 关键词: CALGB; 60301; SORAFENIB; SOLID; TUMORS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn what dose of BAY 43-9006 can be given safely to patients with abnormal liver or kidney function. Another goal of the study is to find out how the body handles the drug depending on liver and kidney function.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。本研究的目的是了解BeAY 43-9006对肝肾功能异常患者的安全剂量。这项研究的另一个目标是找出身体如何根据肝和肾功能来处理药物。